How I treat disseminated intravascular coagulation

被引:168
作者
Levi, Marcel [1 ,2 ]
Scully, Marie [2 ,3 ]
机构
[1] Univ Coll London Hosp NHS Trust, Dept Med, 250 Euston Rd, London NW1 2PG, England
[2] Univ Coll London Hosp, Univ Coll London, Biomed Res Ctr, Natl Inst Hlth Res,Cardiometab Program, London, England
[3] Univ Coll London Hosp NHS Trust, Dept Hematol, London, England
关键词
CRITICALLY-ILL PATIENTS; HUMAN SOLUBLE THROMBOMODULIN; ACTIVATED PROTEIN-C; SEVERE SEPSIS; INTERNATIONAL SOCIETY; SCORING SYSTEM; PROSPECTIVE VALIDATION; PROGNOSTIC VALUE; LIVER-DISEASE; THROMBOCYTOPENIA;
D O I
10.1182/blood-2017-10-804096
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Disseminated intravascular coagulation (DIC) is a condition characterized by systemic activation of coagulation, potentially leading to thrombotic obstruction of small and midsize vessels, thereby contributing to organ dysfunction. At the same time, ongoing consumption of platelets and coagulation proteins results in thrombocytopenia and low concentrations of clotting factors, which may cause profuse hemorrhagic complications. DIC is always secondary to an underlying condition, such as severe infections, solid or hematologic malignancies, trauma, or obstetric calamities. A reliable diagnosis of DIC can be made through simple scoring algorithms based on readily available routine hemostatic parameters. The cornerstone of supportive treatment of this coagulopathy is management of the underlying condition. Additionally, administration of heparin may be useful, and restoration of physiological anticoagulants has been suggested, but has not been proven successful in improving clinically relevant outcomes so far. In patients with major bleeding or at risk for hemorrhagic complications, administration of platelet concentrates, plasma, or coagulation factor concentrates should be considered.
引用
收藏
页码:845 / 854
页数:10
相关论文
共 87 条
[1]   Thrombocytopenia associated with chronic liver disease [J].
Afdhal, Nezam ;
McHutchison, John ;
Brown, Robert ;
Jacobson, Ira ;
Manns, Michael ;
Poordad, Fred ;
Weksler, Babette ;
Esteban, Rafael .
JOURNAL OF HEPATOLOGY, 2008, 48 (06) :1000-1007
[3]   Haemostatic problems in acute promyelocytic leukaemia [J].
Arbuthnot, Carolina ;
Wilde, Jonathan T. .
BLOOD REVIEWS, 2006, 20 (06) :289-297
[4]  
AVVISATI G, 1989, LANCET, V2, P122
[5]   ACQUIRED ALPHA-2-ANTIPLASMIN DEFICIENCY IN ACUTE PROMYELOCYTIC LEUKEMIA [J].
AVVISATI, G ;
TENCATE, JW ;
STURK, A ;
LAMPING, R ;
PETTI, MC ;
MANDELLI, F .
BRITISH JOURNAL OF HAEMATOLOGY, 1988, 70 (01) :43-48
[6]  
Azfar MF, 2017, CLIN INVEST MED, V40, pE49, DOI 10.25011/cim.v40i2.28195
[7]   Prospective validation of the International Society of Thrombosis and Haemostasis scoring system for disseminated intravascular coagulation [J].
Bakhtiari, K ;
Meijers, JCM ;
de Jonge, E ;
Levi, M .
CRITICAL CARE MEDICINE, 2004, 32 (12) :2416-2421
[8]   Disseminated intravascular coagulation in acute leukemia [J].
Barbui, T ;
Falanga, A .
SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2001, 27 (06) :593-604
[9]   Disseminated intravascular coagulation in liver cirrhosis: Fact or fiction? [J].
Ben-Ari, Z ;
Osman, E ;
Hutton, RA ;
Burroughs, AK .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 1999, 94 (10) :2977-2982
[10]   Extended evaluation of recombinant human activated protein C United States trial (ENHANCE US) - A single-arm, phase 313, multicenter study of drotrecogin alfa (activated) in severe sepsis [J].
Bernard, GR ;
Margolis, BD ;
Shanies, HM ;
Ely, EW ;
Wheeler, AP ;
Levy, H ;
Wong, K ;
Wright, TJ ;
Ahmed, M ;
Albertson, T ;
Anas, N ;
Astiz, M ;
Bacon, A ;
Bandi, V ;
Booth, F ;
Bray, W ;
Brilli, R ;
Carlson, R ;
Cheatham, M ;
Conrad, S ;
Cooney, R ;
Cox, M ;
Dolich, M ;
Dries, D ;
Fang, R ;
Forse, R ;
Fricker, R ;
Givens, C ;
Gomez, C ;
Gottlieb, J ;
Graham, D ;
Cropper, I ;
Cross, T ;
Harrison, N ;
Kearl, R ;
Kearney, P ;
Kinasewitz, G ;
Kruse, J ;
Lamberti, J ;
Levy, M ;
Light, R ;
Lin, L ;
Lisco, S ;
Lo, T ;
Linda, L ;
Lodato, R ;
Malave, L ;
Martinez, A ;
Mastuschak, G ;
McDermott, L .
CHEST, 2004, 125 (06) :2206-2216